TDC
XLRN

Thompson Davis & Co’s Acceleron Pharma XLRN Stock Holding History

Thompson Davis & Co’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-499
Closed -$15K – 1233
2017
Q2 		$15K Hold
499
– – 0.02% 558
2017
Q1 		$13K Hold
499
– – 0.02% 629
2016
Q4 		$13K Hold
499
– – 0.02% 634
2016
Q3 		$18K Hold
499
– – 0.03% 523
2016
Q2 		$17K Hold
499
– – 0.03% 519
2016
Q1 		$13K Sell
499
-13
-3% -$378 0.02% 596
2015
Q4 		$25K Buy
512
+104
+25% +$3.74K 0.04% 408
2015
Q3 		$10K Sell
408
-59
-13% -$1.77K 0.01% 660
2015
Q2 		$15K Buy
+467
New +$15.1K 0.02% 636

Other funds holding XLRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

Thompson Davis & Co's XLRN Position: Q3 2017 in Review

Thompson Davis & Co sold out of Acceleron Pharma (XLRN) in Q3 2017, closing a stake of 499 shares — an estimated $15K sold.

Thompson Davis & Co first reported a position in XLRN in Q2 2015 and held it in 9 quarters. The position peaked at $25K in Q4 2015. 149 funds tracked by Wall St. Rank hold XLRN as of Q3 2017.

  • Thompson Davis & Co reported no remaining Acceleron Pharma position as of Q3 2017 after selling out during the quarter.
  • Thompson Davis & Co sold 499 Acceleron Pharma shares in Q3 2017, an estimated $15K.
  • Thompson Davis & Co first reported a position in Acceleron Pharma in Q2 2015 and held it in 9 quarters.
  • Thompson Davis & Co's Acceleron Pharma position peaked at $25K in Q4 2015.
  • 149 funds tracked by Wall St. Rank held Acceleron Pharma as of Q3 2017.

Based on Thompson Davis & Co's 13F filing for Q3 2017, filed 30 Oct 2017.